Skip to Content

Actinium Pharmaceuticals, Inc.

Securities Class Action

  • Date:
  • 5/26/2025
  • Company Name:
  • Actinium Pharmaceuticals, Inc.
  • Stock Symbol:
  • ATNM
  • Class Period:
  • FROM 10/31/2022 TO 8/2/2024
  • Status:
  • Filed
  • Filing Date:
  • 3/27/2025
  • Court:
  • U.S. District Court: Southern District of New York

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE:ATNM) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, both dates inclusive (the “Class Period”). Investors have until May 26, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the Complaint, the Company made false and misleading statements to the market. Actinium misled the market with claims about the strength of the data it submitted to the FDA in support of its Biologics License Application (“BLA”) for Iomab-B. Despite the Company’s claims that it could satisfy the FDA’s guidelines for acceptance and approval of the BLA, it would later admit the need for additional clinical trials to support the BLA filing. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Actinium, investors suffered damages.
 
If you purchased or otherwise acquired Actinium shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Actinium Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: